• Yu Aoh, Tsung-Wei Hou, Cheng-Chia Yang, Ching-Mao Chang, Shih-Pin Chen, I-Ju Tsai, Chin-Wen Cheng, and Chun-Pai Yang.
• Department of Neurology, China Medical University Hospital, Taichung, Taiwan, ROC.
• J Chin Med Assoc. 2024 Apr 1; 87 (4): 350356350-356.

AbstractChronic migraine (CM) is a profoundly debilitating condition that has detrimental clinical and social outcomes. Over the past two decades, novel small-molecule calcitonin gene-related peptide (CGRP) receptor antagonists, known as gepants, and CGRP monoclonal antibodies (mAbs) have been developed, ushering in a new era of migraine-specific treatment. In this review, we discuss the literature investigating the role of gepants for the treatment of CM. Numerous completed and ongoing clinical studies have conclusively demonstrated the safety, tolerability, and efficacy of several gepants for the acute treatment of migraine. However, preventive trials involving gepants have focused on patients with episodic migraine, with atogepant being the only gepant approved for CM prevention by the US Food and Drug Administration at the time of writing. Although some preliminary positive results have been reported, further research is still required to achieve additional advancements in the future. In summary, the effectiveness of gepants for treating individuals with CM are highly expected. This review highlights the development and current progress of gepants for the treatment of CM, focusing both on their role as acute abortive agents and preventive measures and on their concomitant use with other antimigraine medications, such as CGRP mAbs or triptans.Copyright © 2024, the Chinese Medical Association.

21 keywords...

hide…